Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.

Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M.

Liver Int. 2019 Dec 10. doi: 10.1111/liv.14320. [Epub ahead of print]

PMID:
31821716
2.

The nephrology crystal ball: the medium-term future.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Oct 9. pii: gfz199. doi: 10.1093/ndt/gfz199. [Epub ahead of print]

PMID:
31598700
3.

Rituximab in minimal change disease and focal segmental glomerulosclerosis.

Kronbichler A, Gauckler P, Bruchfeld A.

Nephrol Dial Transplant. 2019 Oct 3. pii: gfz205. doi: 10.1093/ndt/gfz205. [Epub ahead of print] No abstract available.

PMID:
31580445
4.

The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation.

Hilderman M, Qureshi AR, Abtahi F, Witt N, Jägren C, Olbers J, Delle M, Lindecrantz K, Bruchfeld A.

Mol Med. 2019 Aug 15;25(1):39. doi: 10.1186/s10020-019-0097-y.

5.

Paving the way towards gender equality: how are we faring in nephrology?

Stevens KI, Soler MJ, Bruchfeld A, Mallamaci F.

Nephrol Dial Transplant. 2019 Aug 9. pii: gfz165. doi: 10.1093/ndt/gfz165. [Epub ahead of print] No abstract available.

PMID:
31407783
6.

Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Antovic A, Mobarrez F, Manojlovic M, Soutari N, De Porta Baggemar V, Nordin A, Bruchfeld A, Vojinovic J, Gunnarsson I.

J Rheumatol. 2019 Aug 1. pii: jrheum.181347. doi: 10.3899/jrheum.181347. [Epub ahead of print]

PMID:
31371653
7.

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.

Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1616. doi: 10.1093/ndt/gfz154. No abstract available.

8.

Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis.

Weiner M, Goh SM, Mohammad AJ, Hrušková Z, Tanna A, Sharp P, Kang A, Bruchfeld A, Selga D, Chocová Z, Westman K, Eriksson P, Harper L, Pusey CD, Tesař V, Salama AD, Segelmark M.

J Rheumatol. 2019 Jul 15. pii: jrheum.190019. doi: 10.3899/jrheum.190019. [Epub ahead of print]

PMID:
31308208
9.

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.

Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1469-1480. doi: 10.1093/ndt/gfz089. Erratum in: Nephrol Dial Transplant. 2019 Sep 1;34(9):1616.

10.

Mild cognitive impairment and kidney disease: clinical aspects.

Viggiano D, Wagner CA, Blankestijn PJ, Bruchfeld A, Fliser D, Fouque D, Frische S, Gesualdo L, Gutiérrez E, Goumenos D, Hoorn EJ, Eckardt KU, Knauß S, König M, Malyszko J, Massy Z, Nitsch D, Pesce F, Rychlík I, Soler MJ, Spasovski G, Stevens KI, Trepiccione F, Wanner C, Wiecek A, Zoccali C, Unwin R, Capasso G.

Nephrol Dial Transplant. 2020 Jan 1;35(1):10-17. doi: 10.1093/ndt/gfz051. No abstract available.

PMID:
31071220
11.

Erratum to Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Apr 12. pii: gfz070. doi: 10.1093/ndt/gfz070. [Epub ahead of print] No abstract available.

PMID:
30977814
12.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Jose Soler M, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1112-1114. doi: 10.1093/ndt/gfz023.

PMID:
30815678
13.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Mar;78(3):399-405. doi: 10.1136/annrheumdis-2018-214245. Epub 2019 Jan 5.

PMID:
30612116
14.

Lancet Countdown paper: what does it mean for nephrology?

Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlík I, Soler MJ, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jan 1;34(1):4-6. doi: 10.1093/ndt/gfy369. No abstract available.

PMID:
30496519
15.

Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.

Bruchfeld A, Lindahl K.

Semin Dial. 2019 Mar;32(2):135-140. doi: 10.1111/sdi.12762. Epub 2018 Nov 26. Review.

PMID:
30475421
16.

Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease.

Xu H, Hashem A, Witasp A, Mencke R, Goldsmith D, Barany P, Bruchfeld A, Wernerson A, Carrero JJ, Olauson H.

Nephrol Dial Transplant. 2019 Dec 1;34(12):2051-2057. doi: 10.1093/ndt/gfy315.

PMID:
30312430
17.

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Levin A, Nair D, Qureshi AR, Bárány P, Heimburger O, Anderstam B, Stenvinkel P, Bruchfeld A, Ungerstedt JS.

Nephron. 2018;140(4):249-256. doi: 10.1159/000492500. Epub 2018 Sep 25.

PMID:
30253414
18.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.

Zoccali C, Arici M, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G.

Clin Kidney J. 2018 Aug;11(4):437-442. doi: 10.1093/ckj/sfy064. Epub 2018 Jul 31.

19.

ERA-EDTA invests in transformation to greener health care.

Blankestijn PJ, Arici M, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G, Zoccali C.

Nephrol Dial Transplant. 2018 Jun 1;33(6):901-903. doi: 10.1093/ndt/gfy092. No abstract available.

PMID:
29800317
20.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.

Zoccali C, Arici M, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1077-1082. doi: 10.1093/ndt/gfy173. Review.

PMID:
29796635
21.

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease.

Gertow J, Ng CZ, Mamede Branca RM, Werngren O, Du L, Kjellqvist S, Hemmingsson P, Bruchfeld A, MacLaughlin H, Eriksson P, Axelsson J, Fisher RM.

Kidney Int Rep. 2017 Jul 29;2(6):1208-1218. doi: 10.1016/j.ekir.2017.07.007. eCollection 2017 Nov.

22.

Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis.

Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A.

J Hepatol. 2018 May;68(5):904-911. doi: 10.1016/j.jhep.2017.12.003. Epub 2017 Dec 9.

23.

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.

Lundberg S, Westergren E, Smolander J, Bruchfeld A.

Clin Kidney J. 2017 Feb;10(1):20-26. doi: 10.1093/ckj/sfw106. Epub 2016 Dec 13.

24.

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londoño MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):585-594. doi: 10.1016/S2468-1253(17)30116-4. Epub 2017 May 30.

PMID:
28576451
25.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

26.

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.

Reddy KR, Roth D, Bruchfeld A, Hwang P, Haber B, Robertson MN, Barr E, Greaves W.

Hepatol Res. 2017 Nov;47(12):1340-1345. doi: 10.1111/hepr.12899. Epub 2017 May 12.

PMID:
28334495
27.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
28.

Late-onset neutropenia after rituximab in ANCA-associated vasculitis.

Knight A, Sundström Y, Börjesson O, Bruchfeld A, Malmström V, Gunnarsson I.

Scand J Rheumatol. 2016 Oct;45(5):404-7. doi: 10.3109/03009742.2016.1138318. Epub 2016 Mar 7.

PMID:
26948245
29.

Macrophage Migration Inhibitory Factor in Clinical Kidney Disease.

Bruchfeld A, Wendt M, Miller EJ.

Front Immunol. 2016 Jan 26;7:8. doi: 10.3389/fimmu.2016.00008. eCollection 2016. Review.

30.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W.

Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5. Erratum in: Lancet. 2015 Nov 7;386(10006):1824.

PMID:
26456905
31.

Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?

Hilderman M, Qureshi AR, Al-Abed Y, Abtahi F, Lindecrantz K, Anderstam B, Bruchfeld A.

Clin Kidney J. 2015 Oct;8(5):599-605. doi: 10.1093/ckj/sfv074. Epub 2015 Aug 25.

32.

Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, Selga D, Chocova Z, Westman K, Eriksson P, Pusey CD, Tesar V, Salama AD, Segelmark M.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1128-35. doi: 10.2215/CJN.00480115. Epub 2015 Jun 22.

33.

[The council for new therapies should immediately revoke their decision on eculizumab].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Westman K.

Lakartidningen. 2015 Jun 11;112. pii: DI7D. Swedish. No abstract available.

34.

[The council for new therapies position on eculizumab is unacceptable].

Karpman D, Fehrman-Ekholm I, Bárány P, Békássy Z, Brandström P, Bruchfeld A, Celsi G, Chromek M, Clyne N, Fellström B, Hansson S, Haraldsson B, Nevéus T, Rippe B, Sartz L, Segelmark M, Stegmayr B, Stenvinkel P, Tufveson G, Westman K.

Lakartidningen. 2015 Jun 9;112. pii: DI3F. Swedish. No abstract available.

35.

Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.

Kronbichler A, Bruchfeld A.

Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8. Review.

36.

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.

Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2015 Jan;30(1):84-91. doi: 10.1093/ndt/gfu259. Epub 2014 Jul 28.

PMID:
25074436
37.

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M.

Am J Nephrol. 2014;39(4):322-30. doi: 10.1159/000360908. Epub 2014 Apr 15. Review.

PMID:
24751753
38.

[23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach].

Altman M, Altman D, Fischler B, Björkstén B, Bruchfeld A, Böhm F, Chrapkowska C, Finder M, Finkel Y, Halmin M, Heyman M, Ilicki A, Kahn R, Karpman D, Katz-Salamon M, Lagercrantz H, Mårtensson T, Nisell H, Rosling H, Sarman I, Wackernagel D, Wennergren G, Wilczek M.

Lakartidningen. 2014 Mar 12-18;111(11):494-5. Swedish. No abstract available.

PMID:
24720027
39.

Rituximab for minimal change disease in adults: long-term follow-up.

Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M.

Nephrol Dial Transplant. 2014 Apr;29(4):851-6. doi: 10.1093/ndt/gft312. Epub 2013 Oct 11.

PMID:
24121763
40.

Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Wendt M, Börjesson O, Avik A, Bratt J, Anderstam B, Qureshi AR, Miller EJ, Gunnarsson I, Bruchfeld A.

Mol Med. 2013 May 20;19:109-14. doi: 10.2119/molmed.2012.00352.

41.

Genetically distinct subsets within ANCA-associated vasculitis.

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG.

N Engl J Med. 2012 Jul 19;367(3):214-23. doi: 10.1056/NEJMoa1108735.

42.

Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis.

Krmar RT, Kågebrand M, Hansson ME, Halling SE, Åsling-Monemi K, Herthelius M, Holtbäck U, Christensson M, Wernerson A, Bruchfeld A.

Clin Nephrol. 2013 Nov;80(5):388-94. doi: 10.5414/CN107431.

PMID:
22541686
43.

Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis.

Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I.

Arthritis Res Ther. 2012 Feb 20;14(1):R36. doi: 10.1186/ar3747.

44.

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D; EUVAS investigators.

Ann Rheum Dis. 2012 Jun;71(6):955-60. doi: 10.1136/annrheumdis-2011-200477. Epub 2011 Nov 29.

PMID:
22128076
45.

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.

Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.

Scand J Rheumatol. 2012 Mar;41(2):116-9. doi: 10.3109/03009742.2011.620573. Epub 2011 Nov 28.

PMID:
22118245
46.

Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension.

Zhang Y, Talwar A, Tsang D, Bruchfeld A, Sadoughi A, Hu M, Omonuwa K, Cheng KF, Al-Abed Y, Miller EJ.

Mol Med. 2012 Mar 27;18:215-23. doi: 10.2119/molmed.2011.00094.

47.

Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis.

Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C, Jayne D.

Am J Kidney Dis. 2011 Apr;57(4):566-74. doi: 10.1053/j.ajkd.2010.10.049. Epub 2010 Dec 30. Review.

48.

High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations.

Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I.

Mol Med. 2011 Jan-Feb;17(1-2):29-35. doi: 10.2119/molmed.2010.00132. Epub 2010 Sep 10.

49.

Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis.

Bruchfeld A, Goldstein RS, Chavan S, Patel NB, Rosas-Ballina M, Kohn N, Qureshi AR, Tracey KJ.

J Intern Med. 2010 Jul;268(1):94-101. doi: 10.1111/j.1365-2796.2010.02226.x. Epub 2010 Feb 18.

50.

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement.

Covic A, Abramowicz D, Bruchfeld A, Leroux-Roels G, Samuel D, van Biesen W, Zoccali C, Zoulim F, Vanholder R; ERA-EDTA ERBP Advisory Board.

Nephrol Dial Transplant. 2009 Mar;24(3):719-27. doi: 10.1093/ndt/gfn608. Epub 2009 Feb 8. No abstract available.

PMID:
19202192

Supplemental Content

Loading ...
Support Center